GlaxoSmithKline's SR One leads $22m series B round for Constellation Pharmaceuticals
SR One, the independent corporate venturing division of healthcare company GlaxoSmithKline, has led the second round of funding for US-based drugs discovery company Constellation Pharmaceuticals by linking up with the venture capital managers of a Colorado-based Indian tribe.
SR One led the $22m series B round for Constellation, with participation from existing VC investors Third Rock Ventures, Column Group, Venrock and Altitude Life Science Ventures.
Altitude manages private equity partnerships on behalf of the GF Private Equity…
